Cancer Pain Diagnostics Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2030

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The cancer burden continues to grow globally, exerting tremendous physical, emotional, and financial strain on individuals, families, communities, and health systems. The Global Cancer Pain Diagnostics Market, analyzed by Astute Analytica, is projected to witness a major rise in its revenue from US$ 6,716.2 Mn in 2021 to US$ 9,951.2 Mn by 2030. The market is registering a growth at a CAGR of 4.6% during the forecast period. 

Cancer is a large group of diseases which can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, go beyond their usual boundaries to invade adjoining parts of the body and/or spread to other organs. The most common cancers are breast, lung, colon and rectum and prostate cancers. Around one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. People with cancer often feel severe or constant pain. The pain they experience depends on the type of cancer they have, the stage the disease is at, and the therapy they receive. The psychological effects of cancer pain can be devastating. Pain makes suffering worse by increasing feelings of helplessness, anxiety, depression, and despair. Cancer-related pain is one of the most prevalent and troubling symptoms impacting cancer patients, with more than 70% of patients reporting it. Despite the availability of excellent medications, up to 50% of cancer patients may experience insufficient pain control. More than 90% of patients in the American Cancer Society's Study of Cancer Survivors-I study reported short-term pain symptoms related to their cancer or its treatment a year after diagnosis; 6% of Australian adult cancer survivors reported pain intensity as "quite a bit/very much" 5 to 6 years after diagnosis; and approximately 20% of childhood cancer survivors (with a mean survival time from diagnosis of 16.5 years) reported recent pain attributed to their previous cancer or cancer treatment.

The market is majorly driven by factors such as niche penetration of healthcare facilities for cancer diagnostics and rising healthcare expenditure & government support worldwide. Early diagnosis is the best alternative for the many cancers that cannot yet be prevented and those that occur despite prevention. When identified early, cancer is more likely to respond to treatment and can result in a greater probability of survival with less morbidity, as well as less expensive treatment. Significant improvements can be made in the lives of cancer patients by detecting cancer early and avoiding delays in care. Further, the healthcare expenditure of many countries is continuously rising, especially expenditure of Asia Pacific countries, thereby fueling the market growth. Furthermore, growing government support worldwide to combat cancer is driving the market growth. For instance, the Health Minister’s Cancer Patient Fund (HMCPF) in India provides financial assistance to poor patients suffering from cancer. 

In 2017, the World Health Assembly passed the Resolution Cancer prevention and control in the context of an integrated approach (WHA70.12) that urges governments and WHO to accelerate action to achieve the targets specified in the Global Action Plan for the prevention and control of NCDs 2013-2020 and the 2030 UN Agenda for Sustainable Development to reduce premature mortality from cancer. However, the accessibility to facilities and high cost of treatment may hinder the market growth over the forecast period. 

Key Insights of the Report: 

• The latest study published by Astute Analytica analyzes Global Cancer Pain Diagnostics Market for the study period of 2017-2030; where historical years are 2017-2020, base year is 2021 and forecast period is 2022-2030.
• The research report offers detailed study of market determinants including market drivers, restraints, opportunities, and trends; along with attractive presentation in the form of impact analysis to gain a simpler and easy comparison view of all market determinants.
• The research study is a compilation of 23 chapters distributed across 278 pages with 70 lists of tables and 107 lists of figures.
• The market is segmented based on drug type, disease indication, and region. The regional analysis also includes the country level analysis of countries such as US, Germany, UK, France, and China, among others.
• The market estimates are presented in terms of value (US$ Mn).
• Along with market estimations, the market study was conducted on the basis of various economic models such as PESTLE and Porter’s five force models.
• A detailed value chain analysis of the industry was conducted. It includes formulation, processing and packaging, distributors, and end-users.
• The competitive dashboard section includes analysis on the basis of Concentration Ratio (CR), based on market size and market presence of key companies.

Key Takeaways from the Global Cancer Pain Diagnostics Market Report:

• Based on drug type, the opioids/ narcotics segment holds the highest share in the cancer pain diagnostics market in 2021 and registers the highest CAGR over the forecast period. This is because strong opioids are a highly successful treatment for cancer pain, with a response rate of 75% and a reduction in average pain intensity from 6 to 3 on a 0–10 pain scale. Further, oxycodone holds the highest segmental share within the opioids/narcotics segment in 2021.
• In terms of disease indication, breast cancer is the highest share segment in 2021 and is further projected to record the highest growth rate over the forecast period. According to the WHO, in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Breast cancer treatment can be highly effective, achieving survival probabilities of 90% or higher, particularly when the disease is identified early. Further, survival of breast cancer for at least 5 years after diagnosis ranges from more than 90% in high-income countries, to 66% in India and 40% in South Africa.
• North America dominates the global cancer pain diagnostics market in 2021. The growth is attributed to the presence of market leaders in the region, well developed healthcare infrastructure, and enhanced healthcare spending. However, due to the rapid rise in cancer prevalence, the Asia Pacific region is recording the highest CAGR over the projection period. Further, an increase in geriatric population coupled with rising health expenditure is further expected to propel the market growth during 2022-2030.

Competitive Dashboard

The key players in the global cancer pain diagnostics market are Biodelivery Sciences International Inc., CK life Science (WEX Pharma), Daiichi Sankyo Co. Ltd., Hisamitsu Pharma Co. Inc., MundiPharma International Ltd., Orexo AB, Pfizer Inc., Teva Pharma Industries Ltd. and Roche Holding AG among others. 

Segmentation Overview

The following are the various segments of the Global Cancer Pain Diagnostics Market:

By Drug Type segment of the Global Cancer Pain Diagnostics Market is sub-segmented into:

• Opioids/Narcotics
  • Morphine
  • Fentanyl
  • Others
• Non-Opioids
  • Acetaminophen
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Nerve Blocks

By Disease Indication segment of the Global Cancer Pain Diagnostics Market is sub-segmented into:

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

By Region segment of the Global Cancer Pain Diagnostics Market is sub-segmented into:

• North America
  • The U.S.
  • Canada
  • Mexico 
• Europe
  • The U.K.
  • Germany
  • France
  • Italy
  • Russia
  • Spain
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Rest of South America
• Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA